DEBIO 1562

Drug Profile

DEBIO 1562

Alternative Names: IMGN-529; K7153A-SMCC-DM1

Latest Information Update: 29 May 2017

Price : $50

At a glance

  • Originator ImmunoGen
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Maytansinoids; Monoclonal antibodies
  • Mechanism of Action CD37 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Diffuse large B cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
  • No development reported Chronic lymphocytic leukaemia

Most Recent Events

  • 23 May 2017 Debiopharm acquires DEBIO 1562 from ImmunoGen
  • 30 Sep 2016 IMGN 529 is available for licensing as of 30 Sep 2016. http://www.immunogen.com/
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Chronic-lymphocytic-leukaemia(Second-line therapy or greater) in Switzerland (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top